PT  - JOURNAL ARTICLE
AU  - Salton, Francesco
AU  - Confalonieri, Paola
AU  - Santus, Pierachille
AU  - Harari, Sergio
AU  - Scala, Raffaele
AU  - Lanini, Simone
AU  - Vertui, Valentina
AU  - Oggionni, Tiberio
AU  - Caminati, Antonella
AU  - Patruno, Vincenzo
AU  - Tamburrini, Mario
AU  - Scartabellati, Alessandro
AU  - Parati, Mara
AU  - Villani, Massimiliano
AU  - Radovanovic, Dejan
AU  - Tomassetti, Sara
AU  - Ravaglia, Claudia
AU  - Poletti, Venerino
AU  - Vianello, Andrea
AU  - Gaccione, Anna Talia
AU  - Guidelli, Luca
AU  - Raccanelli, Rita
AU  - Lucernoni, Paolo
AU  - Lacedonia, Donato
AU  - Foschino Barbaro, Maria Pia
AU  - Centanni, Stefano
AU  - Mondoni, Michele
AU  - Davì, Matteo
AU  - Fantin, Alberto
AU  - Cao, Xueyuan
AU  - Torelli, Lucio
AU  - Zucchetto, Antonella
AU  - Montico, Marcella
AU  - Casarin, Annalisa
AU  - Romagnoli, Micaela
AU  - Gasparini, Stefano
AU  - Bonifazi, Martina
AU  - D’Agaro, Pierlanfranco
AU  - Marcello, Alessandro
AU  - Licastro, Danilo
AU  - Ruaro, Barbara
AU  - Volpe, Maria Concetta
AU  - Umberger, Reba
AU  - Meduri, Umberto
AU  - Confalonieri, Marco
TI  - Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
AID  - 10.1101/2020.06.17.20134031
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.17.20134031
4099  - http://medrxiv.org/content/early/2020/06/25/2020.06.17.20134031.short
4100  - http://medrxiv.org/content/early/2020/06/25/2020.06.17.20134031.full
AB  - Background In hospitalized patients with COVID-19 pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.Methods We conducted a multicenter, observational study to explore the association between exposure to prolonged, low-dose, MP treatment and need for ICU referral, intubation or death within 28 days (composite primary endpoint) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.Results Findings are reported as MP (n=83) vs. control (n=90). The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 ± 9.0 vs. 17.5 ± 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the two groups (p=0.84).Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Randomized controlled studies are needed to confirm these findings.Registration ClinicalTrials.gov. Identifier: NCT04323592Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04323592Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04323592?term=confalonieri&draw=2&rank=1 Funding StatementThis material is the result of work supported with the resources and use of facilities at the University Hospital of Trieste and Memphis VA Medical Center. The contents of this commentary do not represent the views of the US Department of Veterans Affairs nor of the United States or Italian Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the referral Ethics Committee for the Coordinating Centre (University Hospital of Trieste, #CEUR-2020-Os-052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on reasonable external request.